Risk Factors Update Summary

• The company will need to raise additional financing to support business objectives. This might result in operational disruptions.
• The Company has not obtained controlled substance import licenses in any countries, except the UK. This could impact product development and commercialization.
• The company has no mature product candidates and may not be successful in licensing any. This could impact revenue generation.
• The Company may develop products subject to US controlled substance laws and regulations. Failure to comply could lead to delays.
• The company has used substantial cash amounts for funding operations. The need for additional capital is crucial.
• The Company faces significant risks in clinical trials involving cannabinoids and lipid-signaling modulators.
• The company will require a significant additional amount of funds for future product development and trials.
• The Company needs to identify distributors for its products, especially Schedule II products, to reach pharmacies and healthcare providers.
• The company may raise additional funds through various means, impacting ownership and strategic decisions.
• The Company has increased the number of employees from four to five and utilizes approximately twenty-five consultants and contractors.
• The company faces risks related to securities, including potential delisting from Nasdaq Capital Market.
• The Company may face challenges in managing growth, requiring expansion of facilities and staff to execute its business plan.
• The company may need to relinquish valuable rights to product candidates due to funding challenges.
• The Company may not be able to achieve or sustain profitability, having incurred losses since inception.